Literature DB >> 23546839

Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified?

Phillip J Gray1, Jason A Efstathiou.   

Abstract

Although in use for over 40 years, proton beam therapy for prostate cancer has only recently come under public scrutiny, due to its increased cost compared to other forms of treatment. While the last decade has seen a rapid accumulation of evidence to suggest that proton beam therapy is both safe and effective in this disease site, a rigorous comparison to other radiotherapy techniques has not yet been completed. In this review, we provide an in-depth look at the evidence both supporting and questioning proton beam therapy's future role in the treatment of prostate cancer, with emphasis on its history, physical properties, comparative clinical and cost effectiveness, advances in its delivery and future promise.

Entities:  

Mesh:

Year:  2013        PMID: 23546839     DOI: 10.1007/s11934-013-0320-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  60 in total

1.  Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12.

Authors:  John J Coen; Kyounghwa Bae; Anthony L Zietman; Baldev Patel; William U Shipley; Jerry D Slater; Carl J Rossi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-06       Impact factor: 7.038

2.  Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.

Authors:  Nancy P Mendenhall; Zuofeng Li; Bradford S Hoppe; Robert B Marcus; William M Mendenhall; R Charles Nichols; Christopher G Morris; Christopher R Williams; Joseph Costa; Randal Henderson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-17       Impact factor: 7.038

3.  Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer.

Authors:  Carlos Vargas; Amber Fryer; Chaitali Mahajan; Daniel Indelicato; David Horne; Angela Chellini; Craig McKenzie; Paula Lawlor; Randal Henderson; Zuofeng Li; Liyong Lin; Kenneth Olivier; Sameer Keole
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-27       Impact factor: 7.038

4.  Proton therapy in an era of cost containment.

Authors:  Joseph M Herman
Journal:  J Natl Compr Canc Netw       Date:  2011-08-01       Impact factor: 11.908

5.  Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer.

Authors:  Anand Shah; Jason A Efstathiou; Jonathan J Paly; Scott D Halpern; Deborah W Bruner; John P Christodouleas; John J Coen; Curtiland Deville; Neha Vapiwala; William U Shipley; Anthony L Zietman; Stephen M Hahn; Justin E Bekelman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-28       Impact factor: 7.038

6.  Serum testosterone levels after external beam radiation for clinically localized prostate cancer.

Authors:  G K Zagars; A Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-08-01       Impact factor: 7.038

7.  Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer.

Authors:  John J Coen; Jonathan J Paly; Andrzej Niemierko; Elizabeth Weyman; Anita Rodrigues; William U Shipley; Anthony L Zietman; James A Talcott
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-27       Impact factor: 7.038

8.  What happens to testosterone after prostate radiation monotherapy and does it matter?

Authors:  Tom Pickles; Peter Graham
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

9.  Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.

Authors:  Nathan C Sheets; Gregg H Goldin; Anne-Marie Meyer; Yang Wu; YunKyung Chang; Til Stürmer; Jordan A Holmes; Bryce B Reeve; Paul A Godley; William R Carpenter; Ronald C Chen
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

10.  Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer.

Authors:  Alexei Trofimov; Paul L Nguyen; Jason A Efstathiou; Yi Wang; Hsiao-Ming Lu; Martijn Engelsman; Scott Merrick; Chee-Wai Cheng; James R Wong; Anthony L Zietman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-13       Impact factor: 7.038

View more
  5 in total

Review 1.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

2.  Cost-effectiveness of proton beam therapy for intraocular melanoma.

Authors:  James P Moriarty; Bijan J Borah; Robert L Foote; Jose S Pulido; Nilay D Shah
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

Review 3.  Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.

Authors:  Chang-Deng Hu; Richard Choo; Jiaoti Huang
Journal:  Front Oncol       Date:  2015-04-14       Impact factor: 6.244

4.  Comparison of the light charged particles on scatter radiation dose in thyroid hadron therapy.

Authors:  M Azizi; Aa Mowlavi
Journal:  J Biomed Phys Eng       Date:  2014-09-01

Review 5.  Low temperature plasma: a novel focal therapy for localized prostate cancer?

Authors:  Adam M Hirst; Fiona M Frame; Norman J Maitland; Deborah O'Connell
Journal:  Biomed Res Int       Date:  2014-03-13       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.